Susceptibility pathways in Fanconi's anemia and breast cancer
about
Human exonuclease 5 is a novel sliding exonuclease required for genome stabilityCtIP is required to initiate replication-dependent interstrand crosslink repairMolecular pathogenesis and clinical management of Fanconi anemiaFanconi anemia complementation group A (FANCA) protein has intrinsic affinity for nucleic acids with preference for single-stranded formsMutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingThe clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancerSuccesses and Challenges of PARP Inhibitors in Cancer TherapyHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerExploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer TherapyLearning from a paradox: recent insights into Fanconi anaemia through studying mouse modelsPathways for repairing and tolerating the spectrum of oxidative DNA lesionsFanconi anemia and the cell cycle: new perspectives on aneuploidySapacitabine for cancerStructure analysis of FAAP24 reveals single-stranded DNA-binding activity and domain functions in DNA damage responseBiophysical characterization of the interaction between FAAP20-UBZ4 domain and Rev1-BRCT domainA comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assayFancf-deficient mice are prone to develop ovarian tumoursPromoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian CancerLoss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppressionNovel germline PALB2 truncating mutations in African American breast cancer patientsEnhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for CancerAluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia.Modularity-based credible prediction of disease genes and detection of disease subtypes on the phenotype-gene heterogeneous network.Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility.Whole exome sequencing reveals concomitant mutations of multiple FA genes in individual Fanconi anemia patients.Common genetic variants and modification of penetrance of BRCA2-associated breast cancerA knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer dataCtIP mediates replication fork recovery in a FANCD2-regulated manner.Exploring the link between MORF4L1 and risk of breast cancer.The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination.Identification of collaboration patterns of dysfunctional pathways in breast cancer.PALB2/FANCN: recombining cancer and Fanconi anemia.Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families.Differential analysis of ovarian and endometrial cancers identifies a methylator phenotypeNon-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathwayTrapping of PARP1 and PARP2 by Clinical PARP Inhibitors.Genome-wide analysis reveals a role for BRCA1 and PALB2 in transcriptional co-activationGene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells
P2860
Q24301719-35AD2C0B-BFB5-4316-A4FD-DFEA5F932584Q24303573-1365EA5E-DB92-491B-9668-D28B2DAFB58FQ24621696-EF9C7F38-B7EE-4F66-AB15-42E116BE6771Q24631719-FE5B9EFE-1469-4BF7-BE11-03F0B58647A8Q24632270-72A6660A-7B72-4080-9BB2-13E04C647C57Q26766285-D3661FA6-3D43-47D8-A06A-5ECCD9B4F137Q26777131-DC69C14E-2B1F-4342-BCFA-0A92CEFA4381Q26783551-72860199-71C6-4921-80F1-D2FDDAC9C0CFQ26801593-D4FB3E13-6C24-464F-A8A4-6DB845C96CD4Q26863356-BFB05D90-377A-4695-A169-37637262F660Q26992194-92E749BC-DD65-495A-9816-02800A6FBAE2Q27014905-15D4B059-1A35-4500-95AE-F6A05A4264C3Q27024675-9B055247-AB5F-45F1-886B-8B4AFE132A6CQ27679861-FB7F6F40-3AAB-4463-9F19-14C8DB0E6343Q28115633-1BFA01FF-CBD3-4DD6-B8F5-79690B129FF8Q28118199-8BC1CA91-0A08-4C0C-8045-6C2B4010CE3BQ28247935-80FF338F-15BF-4AB5-8C6E-A749A1BB25D3Q28269159-2BF579C3-230B-4932-B7C8-C16D103C04D2Q28512158-9ED85127-BBC8-49E6-A75C-49CB4C9439B9Q28741002-98EE0AA4-45D4-4F0F-99CD-D9BB8837049BQ29147555-25520079-F74F-43BB-B522-DD2F36844DB2Q30371243-042B3EFD-1ED7-40CC-B137-DA11460C375EQ31014656-48A2F458-DBD5-4CD4-9F7C-79179DB06FCBQ33591876-F66FD825-7A82-4F82-B2AB-706348975F4DQ33677756-7F91B8E9-7289-42C4-AA9F-9588292451E4Q33686055-D976484B-AE53-4F80-A3A8-0A6764E7F126Q33742096-D8D08376-7A72-4A07-84B3-8F8CF788176CQ33750026-52D2E459-9C02-40EC-96E7-3A41A868A116Q33784455-618306DB-F972-4FF6-9209-2F29D52AADD6Q33863235-CA496DD9-4E45-412C-B577-0A725E86992BQ33967965-C5BAB9F9-65AA-4114-8E3D-452B8BAB937AQ34028990-5BA7B4CF-F2AD-4300-A80D-780746462155Q34168415-78327BBC-82CA-4485-8A8F-42E75785C904Q34188457-08FA569A-BA3D-4BA9-9F25-037D3201A7C0Q34189765-BD7C7294-8EC8-4BE0-AFF3-F6BF205DAB20Q34248336-DC2FA49B-A692-4760-9D4B-FAE512E20E5EQ34285356-5BB11AD1-B637-4B48-ADF2-E3E4ABB0946BQ34309488-297F2317-E15C-4343-B162-3B11DDDA2658Q34324578-4F0F6402-EE8C-4E0F-B84A-CBE62B9C7CD5Q34406515-6D9AC7EA-902F-4726-A74D-D8E7A2B37989
P2860
Susceptibility pathways in Fanconi's anemia and breast cancer
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Susceptibility pathways in Fanconi's anemia and breast cancer
@ast
Susceptibility pathways in Fanconi's anemia and breast cancer
@en
Susceptibility pathways in Fanconi's anemia and breast cancer
@nl
type
label
Susceptibility pathways in Fanconi's anemia and breast cancer
@ast
Susceptibility pathways in Fanconi's anemia and breast cancer
@en
Susceptibility pathways in Fanconi's anemia and breast cancer
@nl
prefLabel
Susceptibility pathways in Fanconi's anemia and breast cancer
@ast
Susceptibility pathways in Fanconi's anemia and breast cancer
@en
Susceptibility pathways in Fanconi's anemia and breast cancer
@nl
P2860
P3181
P356
P1476
Susceptibility pathways in Fanconi's anemia and breast cancer
@en
P2093
Alan D D'Andrea
P2860
P304
P3181
P356
10.1056/NEJMRA0809889
P407
P577
2010-05-20T00:00:00Z